The White House’s recent announcement that, under President Donald Trump, a series of measures will make In Vitro Fertilization (IVF) more accessible, is a landmark moment for millions of American families. The initiatives, which include deals to lower the price of critical drugs, streamline approval pathways, and create new insurance options for employers, directly tackle the severe financial burden of treatment.
With the cost of a single cycle at between $12,000 and $25,000, the financial barrier not only discourages many from attempting to pursues their dreams of having a family but also causes an estimated 30% to drop out of the grueling process.
While these steps represent significant progress in the United States, they also highlight the vast gap compared to the Israeli model, often cited as a global leader in accessibility and state support.
In Israel, the state, rooted in a culture that deeply values family, almost fully funds fertility treatments, backed by government policy that makes them a national priority. Israel offers a truly comprehensive safety net.
The American model remains a patchwork of market-driven solutions. The US government’s intervention, therefore, is a positive first step, but the road to a holistic model, such as Israel’s, remains long.
Significance of US policy shift
However, the true significance of this American policy shift for the industry is immense.
The announcement is a clear signal of top-level political will. In a climate of investor skepticism, it sends an unmistakable message to the capital markets. The global FemTech market, already valued in tens of billions of dollars, is now receiving a significant boost from the world’s largest economy.
This declaration is a magnet for investment. It validates the market and signals a supportive regulatory environment, which is expected to unlock significant funding for FemTech companies developing the next generation of fertility solutions.
This is where a massive opportunity emerges for medical technology companies, particularly in Israel’s vibrant fem-tech scene.
Israel, a key global hub in the field, is perfectly positioned to seize this moment, ranking fourth worldwide in the number of medical technology companies (over 100) and second in global investment volume. Having attracted hundreds of millions of dollars in recent years, the Israeli ecosystem has a significant focus on pregnancy and fertility solutions, which account for over 40% of its active companies.
This specialization makes Israeli innovation more relevant than ever for the US market. The new policy not only lowers drug prices but also creates demand for more efficient and cost-effective solutions across the entire treatment chain.
Unlocking potential across treatments
Companies like Imma Health are key to unlocking this potential. By developing solutions that reduce the need for frequent clinic visits and reliance on multiple ultrasound scans, they directly address the demand for lower costs and reduce patient stress. Employers and insurance companies offering the new benefit packages will be searching for precisely these technologies, which can deliver better outcomes at a lower cost.
The bottom line is that President Trump’s announcement is more than just financial relief; it’s a strategic inflection point that opens the market to technological innovation. It creates a perfect synergy between supportive government policy and the vast potential of the FemTech industry. The administration has opened the door. For investors and healthcare providers alike, this signals a pivotal moment to back the next wave of innovation.
Technology companies, especially those from established ecosystems, notably Israel’s burgeoning FemTech sector, are now poised to deliver the efficient and accessible tools needed to make the dream of starting a family a reality for millions.
The writer is the CEO of Imma.